​Stemline Therapeutics is a publicly traded, New York based clinical stage biopharmaceutical company which develops novel oncology therapeutics. As of December 2018, the company is developing three clinical stage products candidates, SL-401, SL-801, and SL-701.​

​

​SL-401, also known as ELZONRIS, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a wide range of malignancies. A Phase 2 Trial with SL-401 is enrolling patients with BPDCN (Blastic Plasmacytoid Dendritic Cell Neoplasm). Stemline has submitted a rolling Biologics License Application (BLA) to the FDA for ELZONRIS, which has been granted breakthrough therapy designation (BTD) for the treatment of BPDCN. If successful, the company anticipates the acceptance of the BLA within 60 days of submission and potential U.S. marketing approval by the first quarter of 2019.​

​

​SL-801 is a novel oral small molecule reversible inhibitor of nuclear transport protein. It is in Phase 1 clinical trial for the treatment of solid and hematological cancers. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. Phase 2 trials in adult patients with second-line glioblastoma mutiforme (GBM) has been completed. The data and next steps for the program are being evaluated.​

​Two other product candidates are also in Stemline's pipeline, SL-501 and SL-101, two next generation IL-3R-targeted compounds. The company has also constructed an innovative drug discovery platform (StemScreen).​

Fyber was founded as RNTS Media N.V. in 2010. It is a global advertising technology company. The company is listed on the Prime Standard of the Frankfurt Stock Exchange as Fyber N.V.

Education start up incubators

• ​EDUCATE​
• ​StartEd​
• ​Michelson Runway​
• ​LearnLaunch Accelerator​

​Michelson Runway invests in companies working on programs, products, and/or services that improve equity, access, and efficacy in postsecondary education (higher education, workforce development, and/or lifelong learning).​

​The program lasts for 4 months and is a combination of in-person events in San Francisco, CA and virtual workshops. The accelerator kicks off in person in February and ends with an in-person Demo Day in May. Select startups receive a $25K-$150K equity investment via a SAFE note (an agreement popularized by Y Combinator) with up to an additional $150K investment in follow-on funding.​

​

Standard Cyborg focuses on solving some of the hardest problems in computer vision and computational geometry and giving developers simple and powerful tools to build 3d-aware applications.

​Part-funded by the European Regional Development Fund (ERDF) and in partnership with UCL Engineering, BESA, F6S and Nesta.​

​

Alkahest's research has demonstrated that factors present in young plasma are able to improve brain deficits in pre-clinical models relevant to aging and Alzheimer's. The company is conducting clinical studies in patients with different types of dementia and other neurodegenerative diseases. Two main products in development, AKST/GRF6019 and AKST4290, are entering Phase 2 of clinical trials.

​

AKST/GRF6019 is a proprietary human plasma fraction that has shown evidence of enhancing neurogenesis and improve learning and memory in animals. It has several potential advantages over whole plasma. Clinical trials are being conducted for it's effects on Alzheimer's and Parkinson's Disease. The product is manufactured by Grifols, one of the world's largest producers of FDA approved blood and plasma derived products.​

​

AKST4290 is a small molecule that is orally administered. It's purpose is to inhibit the interaction of CCL11, an inflammatory protein that has been implicated in a number of age related disease. Currently, Phase 2 clinical trials are being run with patients suffering from Wet AMD. It has also concluded Phase 1 clinical trials for a number of other neurodegenerative and inflammatory diseases related to aging.​

​

​Alkahest is a private biotechnology company based in San Carlos, California. The company develops therapies derived from human blood and its components. It focuses on improving vitality and function into old age. Current developments include working on treatments for diseases of aging, with an emphasis on cognitive dysfunction and dementia. ​

Their system uses Hall Effect Technology.

AGILE Space Propulsion is a company spun out of and incubated by Advanced Mobile Propulsion Test (AMPT) in Durango, CO. The company is additively manufacturing advanced rocket engines optimized for in-space applications such as NASA CLPS Landers.

​Real Vegan Cheese won a gold medal and best of track trophy in 2014 in the International Genetically Engineered Machine (iGEM) competition. The team engineering baker's yeast cells to produce milk proteins such as casein which changes structure in cheese formation. Eleven proteins will form the foundation of their cheese. Yeast, genetically engineered yeast to include the genes coding fror these proteins, will be fed carbohydrates and excrete milk. The complete recipe will also include substitutes for animals fat and milk sugar (lactose) are also essential cheese ingredients that will need to come from vegan sources. ​Real Vegan Cheese production process claims to be more sustainable than the standard cheese-making process and can reduce the carbon footprint due to elimination of methane producing cows.​

​

​The same basic principles could be applied to make milk from any other animal casein proteins. For example human breast milk may provide an option to people with allergies to non-human dairy products. The human milk project was put on hold due to concerns about possible autoimmune reactions, by Food and Drug Administration. Real Vegan Cheese plans to make its cheese recipe available for anyone to make it at home.​

​

​In 2018 the team secured private funding which led to the production of four cheese proteins, alpha-s1, alpha-s2, beta casein and kappa casein. Three of those four have been successfully purified. The group is working on reconstituting milk and cheesemaking experiments with these milk proteins in combination with other ingredients such as plant-based fat and sugar. Kappa casein has been used to create a mozzarella-like cheese. ​

​

​

​

​

Akasha stands for 'Advanced Knowledge Architecture for Social Human Advocacy' and is a blockchain-based decentralized social media platform that was founded by Mihai Alisie in 2015. Akasha is built using the Ethereum world computer and is embedded into the Inter-Planetary File System (IPFS). The Akasha decentralized social media platform is built to ensure the platform is resistant against censorship and be unable to be taken offline because it does not have any one central point of failure or lack of bandwidth issues. ​

Yours.org is an online social network that is headquartered in San Francisco, California and was founded in 2016 by Clemens Ley and Ryan Charles. The Yours.org Network built in mechanisms for users to reward other users with Bitcoin Cash (BCH) for creating content.

​

​Content creators can post their content for everyone to see on Yours.org, or put their content behind a pay wall that can be set at any price; Yours.org takes 5% of purchases. Users can choose to cast a 'vote' for content they like and want to support. Each vote is a micro-transaction worth $0.25 of BCH and goes to the content creator and earlier voters, allowing early voters to profit alongside content creators. Users can comment on content on Yours.org but must a commenting fee. Once a user submits a comment they can also profit from votes cast by other users. ​

Funding

Angel round

​On November 17, 2016 Yours.org closed out an angel round of investment with $177, 500 in funding from Digital Currency Group, The Huiyin Group, GaiaX, and Boost VC.

Series A

​On December 24, 2017 Yours.org closed their series A funding round with $1.5 million in funding from Bitmain and nChain. ​